Suppr超能文献

病例报告：与多粘菌素B治疗相关的呼吸麻痹

Case Report: Respiratory paralysis associated with polymyxin B therapy.

作者信息

Ning Yachan, Chu Yanqi, Wu You, Huang Ying, Wang Chunmei, Jiang Li

机构信息

Department of Intensive Care Medicine, Xuanwu Hospital, Capital Medical University, Beijing, China.

Department of Pharmacy, Xuanwu Hospital, Capital Medical University, Beijing, China.

出版信息

Front Pharmacol. 2022 Aug 29;13:963140. doi: 10.3389/fphar.2022.963140. eCollection 2022.

DOI:10.3389/fphar.2022.963140
PMID:36105193
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9465242/
Abstract

Polymyxin B (PMB) and colistin are bactericidal polypeptide antibiotics discovered in 1947 and 1949 for the treatment of gram-negative bacterial infections. Polymyxin was used clinically in the 1950s, but it was gradually replaced by other antibiotics in the 1980s because of its high nephrotoxicity and neurotoxicity. In recent years, the increase of multidrug-resistant negative bacteria has led to the resurgence of polymyxin use. However, its side effects are not clear. Respiratory paralysis caused by PMB-related neuromuscular blockade is a rare but potentially fatal effect. We report a case of respiratory paralysis probably caused by polymyxin B infusion.

摘要

多粘菌素B（PMB）和黏菌素是1947年和1949年发现的用于治疗革兰氏阴性菌感染的杀菌性多肽抗生素。多粘菌素于20世纪50年代开始临床使用，但由于其高肾毒性和神经毒性，在20世纪80年代逐渐被其他抗生素所取代。近年来，多重耐药阴性菌的增加导致了多粘菌素使用的再度兴起。然而，其副作用尚不清楚。由PMB相关的神经肌肉阻滞引起的呼吸麻痹是一种罕见但可能致命的效应。我们报告一例可能由静脉输注多粘菌素B引起的呼吸麻痹病例。

相似文献

1
Case Report: Respiratory paralysis associated with polymyxin B therapy.
Front Pharmacol. 2022 Aug 29;13:963140. doi: 10.3389/fphar.2022.963140. eCollection 2022.
2
Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants Drugs: A Case Report.
J Investig Med High Impact Case Rep. 2016 Mar 14;4(1):2324709616638362. doi: 10.1177/2324709616638362. eCollection 2016 Jan-Mar.
3
Effectiveness and safety of polymyxin B for the treatment of infections caused by extensively drug-resistant Gram-negative bacteria in Thailand.
Infect Drug Resist. 2018 Aug 20;11:1219-1224. doi: 10.2147/IDR.S169939. eCollection 2018.
4
Antimicrobial Activity and Toxicity of the Major Lipopeptide Components of Polymyxin B and Colistin: Last-line Antibiotics against Multidrug-Resistant Gram-negative Bacteria.
ACS Infect Dis. 2015 Nov 13;1(11):568-575. doi: 10.1021/acsinfecdis.5b00085. Epub 2015 Sep 4.
5
Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis.
Int J Antimicrob Agents. 2017 Feb;49(2):233-238. doi: 10.1016/j.ijantimicag.2016.07.023. Epub 2016 Sep 16.
6
Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Int J Antimicrob Agents. 2016 Dec;48(6):592-597. doi: 10.1016/j.ijantimicag.2016.09.010. Epub 2016 Oct 18.
7
Clinical use of intravenous polymyxin B for the treatment of patients with multidrug-resistant Gram-negative bacterial infections: An evaluation of the current evidence.
J Glob Antimicrob Resist. 2021 Mar;24:342-359. doi: 10.1016/j.jgar.2020.12.026. Epub 2021 Jan 21.
8
Rational use of intravenous polymyxin B and colistin: A review.
Med J Malaysia. 2018 Oct;73(5):351-359.
9
Polymyxin B and polymyxin E induce anaphylactoid response through mediation of Mas-related G protein-coupled receptor X2.
Chem Biol Interact. 2019 Aug 1;308:304-311. doi: 10.1016/j.cbi.2019.05.014. Epub 2019 May 25.
10
In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.
Antimicrob Agents Chemother. 2014 May;58(5):2740-6. doi: 10.1128/AAC.02476-13. Epub 2014 Feb 24.

引用本文的文献

1
Case Report: Polymyxin B-induced anaphylactic shock.
Front Pharmacol. 2025 Jun 25;16:1594127. doi: 10.3389/fphar.2025.1594127. eCollection 2025.

本文引用的文献

1
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP).
Pharmacotherapy. 2019 Jan;39(1):10-39. doi: 10.1002/phar.2209.
2
Respiratory Muscle Paralysis Associated With Colistin, Polymyxin B, and Muscle Relaxants Drugs: A Case Report.
J Investig Med High Impact Case Rep. 2016 Mar 14;4(1):2324709616638362. doi: 10.1177/2324709616638362. eCollection 2016 Jan-Mar.
3
Polymyxin use associated with respiratory arrest.
Chest. 2012 Feb;141(2):515-517. doi: 10.1378/chest.11-1483.
4
Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
Ann Pharmacother. 2009 Dec;43(12):1948-55. doi: 10.1345/aph.1M277. Epub 2009 Nov 3.
5
Polymyxins revisited.
Clin Microbiol Rev. 2008 Jul;21(3):449-65. doi: 10.1128/CMR.00006-08.
6
Toxicity of polymyxins: a systematic review of the evidence from old and recent studies.
Crit Care. 2006 Feb;10(1):R27. doi: 10.1186/cc3995.
7
The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients.
Ann Intern Med. 1962 Aug;57:214-29. doi: 10.7326/0003-4819-57-2-214.
8
A method for estimating the probability of adverse drug reactions.
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
9
The polymyxins.
Med Clin North Am. 1970 Sep;54(5):1257-65.
10
Reversible respiratory paralysis associated with polymyxin therapy.
Ann Intern Med. 1968 Feb;68(2):318-27. doi: 10.7326/0003-4819-68-2-318.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验